Technical Analysis for RLMD - Relmada Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 20 DMA Resistance | Bearish | 0.29% | |
| Doji - Bullish? | Reversal | 0.29% | |
| Down 3 Days in a Row | Weakness | 0.29% | |
| Fell Below 20 DMA | Bearish | -0.29% | |
| MACD Bearish Signal Line Cross | Bearish | -2.24% | |
| 200 DMA Resistance | Bearish | -4.12% | |
| Shooting Star Candlestick | Bearish | -4.12% | |
| Lizard Bearish | Bearish Day Trade Setup | -4.12% | |
| Pocket Pivot | Bullish Swing Setup | -4.12% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 20 hours ago |
| 10 DMA Resistance | about 23 hours ago |
| 60 Minute Opening Range Breakout | about 23 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| Rose Above 10 DMA | about 23 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/06/2024
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.2225 |
| 52 Week Low | 1.88 |
| Average Volume | 193,434 |
| 200-Day Moving Average | 3.85 |
| 50-Day Moving Average | 3.24 |
| 20-Day Moving Average | 3.51 |
| 10-Day Moving Average | 3.58 |
| Average True Range | 0.23 |
| RSI (14) | 51.92 |
| ADX | 14.21 |
| +DI | 22.61 |
| -DI | 17.75 |
| Chandelier Exit (Long, 3 ATRs) | 3.30 |
| Chandelier Exit (Short, 3 ATRs) | 3.84 |
| Upper Bollinger Bands | 3.72 |
| Lower Bollinger Band | 3.31 |
| Percent B (%b) | 0.44 |
| BandWidth | 11.63 |
| MACD Line | 0.07 |
| MACD Signal Line | 0.09 |
| MACD Histogram | -0.0236 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.82 | ||||
| Resistance 3 (R3) | 3.84 | 3.75 | 3.77 | ||
| Resistance 2 (R2) | 3.75 | 3.66 | 3.74 | 3.75 | |
| Resistance 1 (R1) | 3.62 | 3.61 | 3.68 | 3.60 | 3.73 |
| Pivot Point | 3.52 | 3.52 | 3.55 | 3.51 | 3.52 |
| Support 1 (S1) | 3.39 | 3.44 | 3.46 | 3.38 | 3.25 |
| Support 2 (S2) | 3.30 | 3.38 | 3.29 | 3.23 | |
| Support 3 (S3) | 3.17 | 3.30 | 3.21 | ||
| Support 4 (S4) | 3.16 |
